US 11,857,606 B2
Therapeutic bacteriocins
Anisha Ambady, Bengaluru (IN); Chemira Biddappa Appaiah, Bengaluru (IN); Deepak Balasubramanian, Chennai (IN); Vivek Daniel Paul, Bangalore (IN); R. Sanjeev Saravanan, Bengaluru (IN); and Umender Kumar Sharma, Bengaluru (IN)
Assigned to BACTOCLEAR HOLDINGS PTE. LTD., Singapore (SG)
Appl. No. 16/954,120
Filed by Bactoclear Holdings Pte. Ltd., Singapore (SG)
PCT Filed Dec. 13, 2018, PCT No. PCT/IN2018/050837
§ 371(c)(1), (2) Date Jun. 15, 2020,
PCT Pub. No. WO2019/116392, PCT Pub. Date Jun. 20, 2019.
Claims priority of application No. 201741045069 (IN), filed on Dec. 14, 2017.
Prior Publication US 2021/0163546 A1, Jun. 3, 2021
Int. Cl. A61K 38/43 (2006.01); A01N 63/50 (2020.01); A01N 63/10 (2020.01); C07K 14/21 (2006.01); C07K 14/26 (2006.01); C12N 9/36 (2006.01)
CPC A61K 38/43 (2013.01) [A01N 63/10 (2020.01); A01N 63/50 (2020.01); C07K 14/21 (2013.01); C07K 14/26 (2013.01); C12N 9/2462 (2013.01)] 10 Claims
 
1. A method of killing Klebsiella pneumoniae or Escherichia coli, comprising contacting the K pneumoniae or E. coli with a bacteriocin that comprises:
a) a receptor-mediated translocation domain comprising the amino acid sequence set forth in the 1-320 segment of SEQ ID NO:10;
b) a receptor binding domain comprising the amino acid sequence set forth in the 322-457 segment of SEQ ID NO:10; and
c) a cargo domain comprising the amino acid sequence set forth in the 475-559 segment of SEQ ID NO:10.